Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836782 | 0.83 | PDE3B (0.61) | EGFRKDRPDE3BPDE3AKMT2A | |
| SCHEMBL3056405 | 0.81 | MAOA (0.62) | CHRNA7PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL16537757 | 0.81 | PDE4A (0.53) | CHRNA7PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL16536586 | 0.81 | PDE4A (0.53) | CHRNA7PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3041636 | 0.80 | MAOA (0.53) | CHRNA7PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL28355190 | 0.77 | MAOB (0.66) | PDE3BPDE3A | |
| SCHEMBL5762667 | 0.76 | CHRNA7 (0.55) | CHRNA7PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5415772 | 0.76 | MEN1 (0.44) | PDE4BPDE4APDE4CPDE4DMEN1 | |
| SCHEMBL3055592 | 0.73 | CHRNA7 (0.52) | CHRNA7PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6881236 | 0.73 | PDE3B (0.45) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | EGFR 1832/4885KDR 2216/4885CHRNA7 2321/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | EGFR 549/4885KDR 4/4885CHRNA7 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.